AzTrials
AzTrials

Intraoperative AnalgesiaNOLGADELSNCT06104059

NOL Guided Analgesia During Elective Laparoscopic Surgery Under General Anesthesia

A study testing Nociception level index (NOL™) and Fentanyl in people with Intraoperative Analgesia, run by Attikon Hospital at 1 site in Greece.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The aim of this study is to investigate the hypothesis that the intraoperative use of the nociception level index NOL can reduce opioid consumption in adult patients undergoing elective laparoscopic surgeries under general anesthesia, as well as to explore its effect on post-operative pain and patient recovery. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Intraoperative Analgesia
What is being tested?
Nociception level index (NOL™) and Fentanyl
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
1 siteGreece
Study dates
20 Apr 2023to 20 Sep 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult patients undergoing planned laparoscopic surgery under general anesthesia.

Who cannot join

  • Emergency surgery.
  • Pregnancy.
  • Drug or alcohol abuse in the last 6 months.
  • Chronic opioid use or patients with chronic pain.
  • Serious comorbidity [cardiac disease (atrial fibrillation, ventricular arrhythmias), liver or kidney disease]
  • Obesity (BMI >35).
Show all 10Show fewer
  • Permanently implanted pacemaker.
  • Patients with CNS disease.
  • Allergy to any of the study drugs.
  • Patients receiving anticholinergics agonists, α2-adrenergic agonists, β1-adrenergic antagonists, antiarrhythmic drugs.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

PARASKEVI Prof MATSOTA contact

6945544563

matsota@yahoo.gr

Greece1 site, 1 recruiting
  • 2nd Department of Anesthesiology, Attikon University Hospital

    Athens, Attica, 12462

    Paraskevi Matsota, Prof

    Paraskevi Mastota, MD, PhD

    Recruiting

Other trials in Greece

About this study

Official title: Ιntraoperative Administration of Opioids Guided by the Nociception Level Index NOL in Elective Laparoscopic Surgeries Under General Anesthesia: Effect on Opioid Consumption, Post-operative Pain and Patient Recovery

The aim of this study is to investigate the hypothesis that the intraoperative use of the nociception level index NOL can reduce opioid consumption in adult patients undergoing elective laparoscopic surgeries under general anesthesia, as well as to explore its effect on post-operative pain and patient recovery.

Read the detailed description

The study is a Prospective Randomized clinical trial. Adult patients (>18y) undergoing elective laparoscopic surgery under general anesthesia will be included.

The patients will be randomized using the "sealed envelope" randomization method into two groups.

Intervention group: in this group, the nociception level index NOL will be used in order to guide intraoperative analgesia. Control group: in this group standard anesthetic care will be provided. Analgesic demands will be treated with bolus doses of iv fentanyl.

All patients will receive the same general anesthesia induction regimen. Patients upon entering the operating room will have standard monitoring applied [Noninvasive Blood Pressure (NIBP), ECG, SpO2] and a venous line placed. The depth of anesthesia will also be monitored by using the BIS sensor and placement of the NOL sensor. Specifically, a sensor (Covidien, BIS™ monitoring system with 3.50 software) will be placed on the forehead (after cleaning with an rubbing alcohol solution) and an NOL sensor (Medasense Biometrics Ltd., PMD200™) on a finger on the opposite upper extremity to that on which the blood pressure cuff will beplaced. Neuromuscular blockade will also be monitored using a neurostimulator (Organon, TOF-Watch SX) to stimulate and record the response of the ulnar nerve to TOF. Before induction to general anesthesia, all patients receive an IV bolus 1mg of midazolam and preoxygenation is performed for 5 minutes with a mask (FiO2: 100%, FGF: 12 l/min). Induction to general anesthesia will be performed with propofol 2.5mg/kg iv and fentanyl 2mcg/kg iv and once a BIS <60 is achieved, rocuronium 0.6mg/kg iv will be administered. At the same time, the patient's ventilation is supported with a mask and bag (FiO2:100%). When TOF=0, endotracheal intubation will be performed. After intubation, maintenance of anesthesia will be achieved by administration of sevoflurane 0.7 MAC in 50% O2/Air and co-administration of iv propofol infusion (75-150mcg/kg/min) with target BIS: 40-60. Subsequently, 8 mg iv dexamethasone and 0.1 mg/kg iv morphine will be administered and an arterial catheter is placed for continuous blood pressure measurement. Before the surgical incision, fentanyl IV 1.5mcg/kg will be administered and the surgical incisions will be infiltrated with a 0.375% ropivacaine solution of 20ml. Intraoperatively, to achieve optimal analgesia, iv fentanyl will be administered according to the group to which the patient has been allocated, as described above. Half an hour before the end of the operation, 1g paracetamol iv and 4mg ondasetron iv will be administered and 20 minutes before the end of the surgical procedure, the propofol infusion will stop.

Reversal of peripheral neuromuscular blockade will be perfomed using sugammadex: 2-4mg/kg, depending on the indication of the neurostimulator. The patient will be extubated if TOF=4 \& TOF ratio ≥0.9 and BIS >80. Subsequently, the patient will be transferred to the Post Anesthesia Care Unit (PACU).

In PACU, intensity of postoperative pain will be assessed every 15 minutes with the Visual analogue scale (VAS, 0-10) and for a score >4, morphine 1mg iv bolus will be administered (up to 0.15mg/kg morphine in total for each patient including the intraoperative dose) until the patient is released from PACU.

Patient recovery will be assessed using the Post Anesthesia Recovery Score (PAR-Score), i.e. the Modified Aldrete score initially as soon as the patient is transferred to the PACU and patients will be released from PACU once they have score ≥9. The length of stay in the PACU until a score ≥9 is reached will also be recorded.

Any events or adverse effects (respiratory depression, lethargy, nausea, vomiting, itching, etc.) will also be recorded in the PACU.

Being tested
Nociception level index (NOL™), Fentanyl

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Nociception level index (NOL™)Device

    If a NOL value >25 persists for >1 minute a bolus of iv fentanyl 0.5mcg/kg will be given and reassessment of the NOL value will continue every 5 minutes. If NOL index value: 10-25 is not reached within 10 minutes, fentanyl 0.5mcg/kg iv is re-administered.

  • FentanylOther

    Bolus doses of iv fentanyl 0.5 mcg/kg will be administered based on the judgment of the anesthesiologist in charge.

Study groups in NCT06104059
Study groupRoleWhat they receive
Nociception level index (NOL™)Active comparatorThe nociception level index NOL will be used in order to quide intraopertaive analgesia.
Receives: Device: Nociception level index (NOL™)
Standard of careActive comparatorIntraoperative analgesia will be based on common practice, i.e. changes in hemodynamic parameters.
Receives: Other: Fentanyl

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Intraoperative total consumption of opioids

    Intraoperative total consumption of opioids will be calculated in all patients.

    Measured: Up to 30 minutes after the end of operation

Secondary outcomes (2)
  1. Postoperative administration of opioids in PACU

    Total consumption of opioids will be calculated in all patients

    Measured: Until the patient is released from PACU (up to 24 hours)

  2. Intensity of postoperative pain in PACU

    In PACU, intensity of postoperative pain will be assessed every 15 minutes with the Visual analogue scale, a 10 points scale (0= no pain and 10= worst pain)

    Measured: Until the patient is released from PACU (up to 24 hours)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Oct 2023
  2. Study start20 Apr 2023
  3. Primary completion20 Sep 2027 (estimated)
  4. Study completion20 Sep 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Prospective, Randomized clinical trial
Masking
Single blind
Who is masked
Participant
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06104059
Sponsor's protocol ID
NOLGADELS
Acronym
NOLGADELS
Status last verified
Mar 2026
First submitted
22 Oct 2023
Last updated
30 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Nociception level index (NOL™) and Fentanyl in people with Intraoperative Analgesia, run by Attikon Hospital at 1 site in Greece.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 30 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact PARASKEVI Prof MATSOTA (6945544563, matsota@yahoo.gr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Intraoperative total consumption of opioids (time frame: Up to 30 minutes after the end of operation). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in